Compared with the LDM- and ADR-treated mice, mice treated with anti-CD19(Fab)-LDM at doses of 2, 4, and 6 nmol/kg showed a significant inhibition of tumor growth in a dose-dependent manner in both the BJAB and BJAB/ADR xenograft models (P < 0.05) as shown in Figure 6A. This evidence concerns the gene CD19 and neoplasm.